1. FDA. CBER Expanded Access Submission Receipt Reports. Published online March 3, 2022. Accessed July 18, 2022. https://www.fda.gov/vaccines-blood-biologics/cber-expanded-access-submission-receipt-reports
2. Mesoblast International Sàrl. Intermediate-Size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19). 2022. Accessed August 2, 2022. https://clinicaltrials.gov/ct2/show/NCT04456439
3. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon;Mendicino;Cytotherapy,2019
4. Promoting Patient Interests in Implementing the Federal Right to Try Act;Lynch;JAMA,2018
5. Stem Cell Businesses and Right to Try Laws;Sipp;Cell Stem Cell,2019